Basic fibroblast growth factor (bFGF) is a multifunctional growth factor that may play a significant role in atherosclerotic vascular complications in patients with type 2 diabetes. This study was designed to investigate the association between genetic polymorphisms (-553 T/A, -834 T/A and -921 C/G) in the promoter region of the bFGF gene and myocardial infarction (MI) in 443 patients with type 2 diabetes (149 with MI and 294 with no history of coronary artery disease). The -553 T/A, -834 T/A and -921 C/G polymorphisms of the bFGF gene were found not to be risk factors for MI in patients with type 2 diabetes. The impact of bFGF gene polymorphisms on serum bFGF levels was also investigated and significantly higher serum levels of bFGF were demonstrated in diabetes patients with the TA genotype of the -553 T/A polymorphism compared with diabetes patients with the TT wild type genotype (9.0 ± 5.6 ng/l versus 3.0 ± 1.9 ng/l, respectively). Thus, the tested bFGF gene polymorphisms cannot be used as genetic markers for MI in diabetic Caucasians.
Introduction
Type 2 diabetes mellitus is a major risk factor for cardiovascular disease. 1 Diabetic atherosclerosis is characterized by increased inflammation, neovascularization and intra-plaque haemorrhage. 1 Inappropriate production of various growth factors, including basic fibroblast growth factor (bFGF), may contribute to this inflammatory micro-angiopathic process, leading to plaque rupture and coronary thrombosis. 1 -3 Increased serum levels of bFGF protein have been observed among patients with acute myocardial infarction (MI) and unstable S Kariž, D Grabar, M Krkovič et al. bFGF gene polymorphisms are not associated with MI angina pectoris. 4,5 Furthermore, abnormal expression of fibroblast growth factors has been demonstrated in atherosclerotic lesions in coronary arteries. 6, 7 The bFGF gene is upregulated in diabetes mellitus and is implicated in diabetesinduced vascular complications. 8 Levels of bFGF mRNA have been shown to increase several fold in the eye, heart and brain of diabetic rats. 9 Additionally, increased levels of bFGF mRNA have been demonstrated in peripheral monocytes from diabetic patients with coronary artery disease (CAD). 10 The human bFGF gene is located on the long arm of chromosome 4 at bands q26 -q27. 11 Polymorphisms within the promoter region of the bFGF gene may interfere with existing transcription factor binding sites or produce new binding sites and, therefore, influence bFGF gene expression. 12 This casecontrolled, cross-sectional study was designed to investigate a possible association between the bFGF gene polymorphisms (-553 T/A, -834 T/A and -921 C/G) and MI among patients with type 2 diabetes in a Slovene Caucasian population. The impact of the bFGF gene polymorphisms on serum levels of bFGF protein was also investigated.
Patients and methods

STUDY POPULATION AND CLINICAL ASSESSMENT
The study population of this case-control, cross-sectional analysis consisted of patients with type 2 diabetes of > 10 years ' National Medical Ethics Committee of Slovenia approved the research protocol. After written informed consent was obtained from the patients and controls, a detailed interview was undertaken.
The diabetes patients were grouped according to whether they also had MI (MI group), or whether they had no history of CAD (including negative history of MI or angina pectoris), no signs of ischaemia on electrocardiogram and no ischaemic changes during submaximal stress testing (control group). Diagnosis of MI was made according to the redefined criteria of the Joint European Society of Cardiology/American College of Cardiology Committee. 13 The diabetes patients with MI were eligible for inclusion in the study 1 -9 months after the acute event. Patients in both the MI group and the control group were from independent families. All the subjects enrolled in the study were Slovenes of Slavic origin.
Arterial hypertension and cigarette smoking were defined as binary variables. Patients were classified as having type 2 diabetes according to current American Diabetes Association criteria for the diagnosis and classification of diabetes. 14 Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ). Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were determined by standard biochemical methods.
GENETIC ANALYSIS: DETECTION OF bFGF GENE POLYMORPHISMS
Genomic DNA was isolated from peripheral blood lymphocytes by standard methods and stored at -20°C. Genotyping was carried out by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Two investigators blinded for the source of the DNA sample performed the S Kariž, D Grabar, M Krkovič et al. bFGF gene polymorphisms are not associated with MI genotype analyses.
The PCR reactions for detection of the -553 T/A, -834 T/A and -921 C/G polymorphisms were performed in a total volume of 15 µl, containing 0.3 µl 10 mM dNTP (final concentration 0.2 mM; Promega, Madison, WI, USA), 1.5 µl of 10× PCR buffer (Applied Biosystems, Foster City, CA, USA), 0.9 µl 25 mM MgCl 2 (final concentration 1.5 mM; Applied Biosystems), 0.6 µl 10 µM of each unique primer oligonucleotide (forward and reverse) for each of the three polymorphisms ( Table 1, Table 1 . The PCR products for the -553 T/A and -921 C/G polymorphisms were digested with BseNI restriction enzyme (Fermentas Life Sciences, Glen Burnie, MD, USA) for 5 h at 65°C, and PCR products for the -834 T/A polymorphism were digested with the SspI restriction enzyme (Fermentas Life Sciences) for 5 h at 37°C. All products of restriction enzyme digestion underwent electrophoresis on a 3.0% agarose gel (Sigma-Aldrich, St Louis, MO, USA) and were then visualized using SYBR ® Green I (Molecular Probes, Eugene, OR, USA) staining.
SERUM bFGF ASSAY
Serum levels of bFGF were analysed in a subpopulation of consecutive type 2 diabetes patients who did not have CAD and in control subjects without diabetes. The bFGF assay employed the quantitative sandwich enzyme immunoassay technique using the Quantikine ® HS Human FGF basic immunoassay kit (R&D Systems, Minneapolis, MN, USA), performed according to the manufacturer's instructions. Briefly, a microplate pre-coated with a monoclonal antibody specific for bFGF was incubated with 150 µl/well of serum for 3 h at room temperature. The microplate was then washed six times (400 µl/well) with the washing buffer provided with the kit, before adding an alkaline phosphatase-linked anti-FGF monoclonal antibody and incubating for 2 h at room temperature. The microplate was then washed as described above before addition of the substrate, reconstituted lyophilized NADPH, and measurement of optical density at 490 nm.
TABLE 1: The primers and reaction conditions used in the polymerase chain reaction (PCR) for the detection of the -553 T/A, -834 T/A and -921 C/G polymorphisms
Polymorphism PCR primer pairs PCR cycling conditions
Initial denaturation at 95°C for 5 min, then 30 cycles each at: 
STATISTICAL ANALYSIS
Statistical analysis was performed using the SPSS ® statistical package, version 14.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The χ 2 test was used to compare discrete variables, genotypic distributions and Hardy-Weinberg equilibrium. Continuous clinical data were compared using the unpaired Student's t-test. A P-value of < 0.05 was considered to be statistically significant.
Results
The study population consisted of 443 patients with type 2 diabetes of > 10 years' duration: 149 in the MI group and 294 in the control group. Their clinical and laboratory characteristics are shown in Table 2 . The type 2 diabetes patients with MI were significantly younger, predominantly male, had a higher incidence of cigarette smoking and had significantly higher LDL cholesterol levels compared with the control group of type 2 diabetes patients without CAD (P < 0.001 for all comparisons). They also had significantly higher total cholesterol levels, significantly lower HDL cholesterol levels and a significantly longer duration of type 2 diabetes than the control group (P < 0.05 for all comparisons). There were no significant differences in BMI, the incidence of hypertension, or triglyceride levels between the two groups.
The bFGF genotype distributions in type 2 diabetes patients in the MI and control groups were compatible with Hardy-Weinberg expectations (bFGF -553T/A: MI group χ 2 = 0.48, control group χ 2 = 1.12; bFGF -834 T/A: MI group χ 2 = 0.31, control group χ 2 = 0.34; bFGF -921 C/G: MI group χ 2 = 3.37, control group χ 2 = 3.38). None of the genotype distributions for the bFGF gene was statistically significantly different between any of the groups and the -553 T/A, -834 T/A and -921 C/G polymorphisms were shown not to be risk factors for MI in patients with type 2 diabetes (Table 3) . 
Patients with type 2 diabetes
MI group
TABLE 2: Clinical and laboratory characteristics of patients with type 2 diabetes and myocardial infarction (MI group) compared with control patients with type 2 diabetes and no history of coronary artery disease (control group) bFGF gene polymorphisms are not associated with MI
Serum levels of bFGF protein analysed in a subpopulation of 80 consecutive type 2 diabetes patients who did not have CAD and in 26 subjects without diabetes were significantly higher in the type 2 diabetes patients (10.9 ± 8.2 ng/l versus 5.6 ± 4.2 ng/l; P = 0.02). Significantly higher bFGF serum levels were also demonstrated in type 2 diabetes patients with the TA genotype (n = 16) of the -553 T/A polymorphism compared with those with the TT wild type genotype (n = 64) (9.0 ± 5.6 ng/l versus 3.0 ± 1.9 ng/l; P = 0.01). No statistically significant difference in serum bFGF levels was found between type 2 diabetes patients with the TA genotype (n = 6) of the -834 T/A polymorphism and those with the TT wild type genotype (n = 72) (2.8 ± 1.8 ng/l versus 8.8 ± 9.5 ng/l) or between the type 2 diabetes patients with the CG genotype (n = 14) of the -921 CG polymorphism and the CC wild type genotype (n = 64) (8.3 ± 6.8 ng/l versus 8.5 ± 9.5 ng/l).
Discussion
In this cross-sectional study, the -553 T/A, -834 T/A and -921 C/G polymorphisms of the bFGF gene were shown not to be risk factors for MI in patients with type 2 diabetes. The allele frequencies and genotype distributions in the present study were in agreement with previously published data on Caucasians of Czech nationality. 12 It is known that bFGF plays an important role in vascular responses by increasing endothelial cell proliferation, stimulating migration and promoting angiogenesis. 15 -17 Since bFGF is produced by plaque mast cells and may promote plaque progression and neovascularization, 18 1 The present study found serum levels of bFGF in patients with diabetes to be significantly higher than in control subjects without diabetes and these findings were in accordance with the report by Zimering and Eng, 19 who found elevated serum levels of bFGF in male diabetic patients with proteinuria. Furthermore, Panutsopulos et al. 10 observed increased bFGF mRNA expression in peripheral monocytes from diabetic patients with CAD. 10 Increased bFGF in patients with diabetes is most probably due to the effect of high glucose concentrations on transcription of the bFGF gene. 20 In the present study, significantly higher serum levels of bFGF were demonstrated in 16 diabetes patients with the TA genotype of the -553 T/A polymorphism compared with 64 diabetes patients with the TT wild type genotype. Similarly, Schulz et al. 21 found an association between the -223 C/T polymorphism, bFGF gene expression and plasma levels of bFGF in atherosclerosis, while Beranek et al. 22 demonstrated significantly higher bFGF plasma levels in diabetic patients with proliferative diabetic retinopathy and the -754C allele of the bFGF gene. The aforementioned results, as well as those from the present study, support the presumption that the level of bFGF expression is genetically based.
Interestingly, genetic polymorphisms in the promoter region of the bFGF gene have been found to be associated with proliferative diabetic retinopathy in patients with type 2 diabetes. 23 Proliferative diabetic retinopathy has also been shown independently to predict cardiovascular disease events 24 and coronary heart diseaserelated death 25 in diabetic patients, suggesting the presence of common background pathways for diabetic micro-and macrovascular disease.
The lack of an association between the polymorphisms in the promoter of the bFGF gene and MI in the present study may be due to the multifactorial nature of CAD. This negative result may also be attributable to survival bias, especially in diabetic patients with MI, which is associated with increased early mortality. For example, even after the first cardiac event, 50% of patients with diabetes may die within 1 year and half of those who die do so before they reach the hospital. 26 Furthermore, the exclusion of CAD on the basis of a negative history of MI or angina pectoris and the absence of ischaemic changes on electrocardiogram and during exercise stress testing, has some disadvantages. It is not possible to rule out the possibility that a proportion of diabetes patients in the control group had asymptomatic CAD. In a previous study, 18% of asymptomatic diabetic patients with a negative result during exercise stress testing presented silent CAD with significant (≥ 70%) angiographically-documented coronary stenosis. 27 In conclusion, the -553 T/A, -834 T/A and -921 C/G polymorphisms of the bFGF gene are not risk factors for MI in patients with type 2 diabetes and they cannot, therefore, be used as genetic markers for MI in Caucasians with type 2 diabetes. The association between the -553 T/A polymorphism and serum levels of bFGF in diabetic patients deserves further investigation in a larger study.
